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Prostate cancer is the second leading cancer in men world-wide. Due to its 
heterogeneous nature, a considerable amount of research effort has been dedicated 
in identifying effective clinical biomarkers with a focus on proteins, messenger RNA 
and microRNAs [1]. However, there is limited data on the role and expression of 
long noncoding RNAs (lncRNAs) in prostate cancer exosomes [2]. This array dataset 
which is linked to our publication describes the profiling of human lncRNAs in 
prostate cancer and their exosomes from five different cell lines [3]. From this 
dataset, we identified a list of statistically significant prostate cancer lncRNAs which 
are differentially expressed in the exosomes compared to their parent cell lines. This 

















Homo sapiens/ Prostate Cancer Cell Lines: LNCaP, PC3, 
DU145, VCaP, / Healthy Prostate Cell Lines: PNT2 
Sex Male 
Sequencer or array 
type 
Agilent Oligo nucleotide array 
Data format Raw text files 
Experimental factors Tumor vs normal cell line 
Experimental features Extraction of total RNA from exosomes of prostate cancer 
and healthy cell lines, followed by lncRNA profiling using the 


















Direct link to deposited data 
[http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81034] 
 
Experimental Design, Materials and Methods 
The experiment design and data analysis pipeline is shown in Figure 1. In the 
following sections, we review the experiment design, quality assessment of the 
prepared data and the analysis pipeline for this dataset. 
 
Tissue Culture of prostate cancer cell lines 
Prostate cancer cell lines, LNCaP, PC3, and DU145 were cultured in RPMI medium, 
VCaP cells were grown in F12:DMEM and PNT2 cell lines in defined KSFM 
(Invitrogen, USA). All cells were incubated at 37 °C in 5% CO2, and supplemented 
with 1% v/v penicillin, streptomycin, glutamine and 10% v/v fetal calf serum. As Fetal 
Calf Serum contains exosomes of bovine origin all media were depleted of these 
bovine exosomes. To remove bovine exosomes, we utilized the ultracentrifugation 













Isolation of exosomes using ultracentrifugation 
Harvested culture was centrifuged twice, firstly at 500g for 30 minutes, and then at 
2,000g for 10 minutes to remove dead cells and any debris. The resulting 
supernatant was then centrifuged at 10,000g for 30 minutes to separate micro-
particles and other proteins from the exosomes. The supernatant was collected from 
this step and then centrifuged at 100,000g for 120 minutes to obtain an exosomal 
pellet. The supernatant was discarded, and the pellet retained. The exosomal pellet 
was then re-suspended in PBS and centrifuged at 100,000g for 90 minutes. This 
resulting pellet contains the exosomes which was subjected to RNA isolation. 
 
RNA extraction procedures 
RNAzol RT (Molecular Research Center, USA) was used to extract total RNA from 
both cellular and exosomal sources [4]. 1mL of RNAzol was added to the exosomal 
pellet and homogenised using a blunt needle syringe. This homogenate is added to 












then centrifuged at 4°C, at 12,000g for 15 minutes. 1mL of the resulting supernatant 
was removed and purification performed via the addition of 5uL of 4-bromoanisole. 
The sample was incubated for 3-4 minutes, and centrifuged at 12,000g, 4°C, for 10 
minutes. The supernatant was removed from the sample, and 1 volume of 
isopropanol was added with 5uL of glycogen (25mg/mL) to precipitate the RNA. This 
mixture was then incubate on dry ice for 15 minutes followed by centrifugation at 
12,000g, 4°C, for 10 minutes. The resulting RNA pellet was then washed twice in 
75% ethanol and centrifuge at 8,000g for 5 minutes to collect the pellet. After 
discarding the supernatant, the exosomal RNA pellet was solubilized with the 
addition of 50uL of RNA/DNA free water. 
 
Preparation of lncRNAs for hybridization to Agilent arrays 
RNA Integrity and concentration was assessed post RNA extraction and prior to 
sample labeling. The sample RNA integrity number (RIN) was determined using a 
Bioanalyzer 2100 to assess RNA quality. RNA concentration, protein contamination 












NanoDrop ND-1000. Agilent Low RNA Input Linear Amplification Kit PLUS was used 
for sample amplification and labeling. Hybridization was performed using the Agilent 
SureHyb Hybridization Chambers. The labeled cRNAs were hybridized onto the 
Human lncRNA array v2.0 (8 x 60K, Arraystar) for the global profiling of 33,045 
human lncRNAs. The lncRNAs in this array were collected from databases such as 
RefSeq, UCSC Known genes, and Ensembl. After washing the array slides, they were 
scanned using the Agilent Scanner G2505B. Agilent Feature Extraction software 
(version 10.7.3.1) was then used to analyze the acquired array images for 1) outlier 
analysis, 2) net signal statistics analysis, 3) local background statistical analysis, and 
4) reproducibility analysis of the signals.  
 
Data normalization and analysis 
Quantile normalization was performed using the GeneSpring GX v11.5.1 software 
package (Agilent Technologies). After quantile normalization of the raw data, 
lncRNAs of which 6 out of 10 samples had flags in Present or Marginal (“All Targets 












for differentially expressed LncRNA screening. In the next step, quality assessment of 
lncRNA data for the different cell lines was performed by 1) investigating the box 
plot of the normalized intensity values to compare the distributions of intensities 
among different samples (Figure 2A) and 2) inspecting the scatter plot of the log2 
scaled values of the averaged normalized signal values of the exosomes versus the 
cells of each cell line to assess the lncRNA expression variations (Figure 2B). To 
identify differentially expressed lncRNA, a fold change filtering with a threshold of 
fold change >=2.0 was performed. Generation of the heatmaps and the hierarchical 
cluster analysis was performed using Agilent GeneSpring GX v11.5.1.  
Discussion 
Our dataset represents a novel categorization of lncRNA levels in prostate cancer 
exosome and their parental lineages. We have profiled four common prostate cancer 
cell lines and compared these to the normal PNT2 cells. Our array data suggested 
that lncRNAs are present in abundance in both healthy and prostate cancer 
exosomes. We normalized the data using quantile normalization and then filter the 












down-regulated and 19 upregulated lncRNAs which were common to these 
exosomes. Furthermore, these exosomal lncRNAs appeared to be enriched for 
miRNA seeds with a preference for miR-17, miR-18a, miR-20a, miR-93, miR-106b 
and the let-7 family members [3]. With these observation, we put forward the notion 
that lncRNAs can act as miRNA sponges and their specific enrichment in exosomes 
is an important step in prostate cancer carcinogenesis. The heat maps clearly 
showed the similarities and differences in the lncRNA expression between cancer 
exosomes/cells versus the normal exosomes/cells (Figure 3). With this dataset, it may 
be possible to discover potential exosomal lncRNAs which can be utilised for 



















Figure 1. Experimental Overview of the project and the data processing pipeline. 
Four difference prostate cancer cell lines were grown and the media harvested from 
these cell lines were used to isolate exosomes. Total RNA was then extracted from 
both cellular and exosomal sources. Integrity and concentration of RNA were 
assessed after RNA extraction and prior to sample labeling. Agilent low RNA input 
linear amplification kit PLUS was used for sample amplification and labeling. After 
washing, slides were scanned with the Agilent DNA Microarray Scanner. Data was 
extracted using Agilent feature extraction software. Normalization and further data 
analysis was performed using GeneSpring v11.5.1 software. 
 
Figure 2. A) Box plot representing intensities distributions B) A representative 
scatter plot of PC3 exosomes vs PC3 cell. The green lines indicate fold change lines 













Figure 3. A heatmap representing the differential lncRNA expression in the parental 
prostate cancer cell lineages and their exosomes. “red” indicates high relative 

















1. Khoury S, Tran N: Circulating microRNAs: potential biomarkers for common malignancies. 
Biomark Med 2015, 9(2):131-151. 
2. Walsh AL, Tuzova AV, Bolton EM, Lynch TH, Perry AS: Long noncoding RNAs and prostate 
carcinogenesis: the missing 'linc'? Trends Mol Med 2014, 20(8):428-436. 
3. Ahadi A, Brennan S, Kennedy PJ, Hutvagner G, Tran N: Long non-coding RNAs harboring miRNA 
seed regions are enriched in prostate cancer exosomes. Scientific reports 2016, 6:24922. 





























Figure 2  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
Figure 3 
